Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immulytic platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1, which is in Phase I/II clinical trials for a range of solid tumors; and that is in Phase II clinical trials for patients with cutaneous squamous cell carcinoma. It is also developing RP2, which is in Phase I clinical trials for an anti-CTLA-4 antibody-like protein in order to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trials to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.
IPO Year: 2018
Exchange: NASDAQ
Website: replimune.com
Date | Price Target | Rating | Analyst |
---|---|---|---|
8/28/2024 | $17.00 | Buy | ROTH MKM |
4/17/2023 | $44.00 | Overweight | Piper Sandler |
11/19/2021 | $52.00 | Overweight | Piper Sandler |
10/15/2021 | $60.00 | Buy | BTIG Research |
8/23/2021 | $55.00 → $49.00 | Outperform | SVB Leerink |
8/9/2021 | $56.00 → $55.00 | Outperform | SVB Leerink |
Data from the IGNYTE primary analysis shows clinically meaningful activity across all subgroups, including those who had received prior anti-PD1 and anti-CTLA-4 or had primary resistance to anti-PD1 Injected and non-injected lesions responded with similar frequency, depth, duration and kinetics WOBURN, Mass., Sept. 15, 2024 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ:REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced that data from the primary analysis of the IGNYTE clinical trial of RP1 combined with nivolumab were presented by Caroline Robert, M.D., Ph.D. of Gustave Roussy as a late breaking abstract durin
WOBURN, Mass., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ:REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced it has completed a successful pre-Biologics License Application (pre-BLA) meeting with the U.S. Food and Drug Administration (FDA) that supports the Company's plans to submit a BLA for RP1 (vusolimogene oderparepvec) for the treatment of anti-PD1 failed melanoma via the accelerated approval pathway in 2H 2024. "This successful pre-BLA meeting confirmed that the accelerated approval path is available for RP1 in anti-PD1 failed melanoma," said Sushil Patel, Ph.D., Chief Executive Officer a
WOBURN, Mass., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ:REPL), a clinical stage biotechnology company pioneering the development of a novel class of oncolytic immunotherapies, today announced that Madhavan (Madhu) Balachandran was elected to Replimune's Board of Directors at the Company's annual meeting of stockholders. "We are thrilled to welcome Madhu to Replimune's Board of Directors," said Sushil Patel, Ph.D., Chief Executive Officer of Replimune. "Madhu is an accomplished life sciences industry executive with decades of valuable experience in commercial development, manufacturing and operations. We look forward to working with Madhu as we continue to prepare f
WOBURN, Mass., Aug. 22, 2024 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ:REPL), a clinical stage biotechnology company pioneering the development of a novel class of oncolytic immunotherapies, today announced that a late-breaking abstract presenting the primary analysis of the IGNYTE clinical trial has been selected for oral presentation at the European Society for Medical Oncology (ESMO) Congress 2024 being held September 13-17, 2024, in Barcelona. Presentation Details: Title: Primary efficacy, safety, and survival data from the registration-intended cohort of patients with anti-PD-1-failed melanoma from the IGNYTE clinical trial with RP1 combined with nivolumabPresentation Sessio
WOBURN, Mass., Aug. 13, 2024 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ:REPL), a clinical stage biotechnology company pioneering the development of a novel class of oncolytic immunotherapies, today announced that the first patient has been randomized and dosed in the IGNYTE-3 study – a global Phase 3 clinical trial assessing the efficacy and safety of RP1 (vusolimogene oderparepvec) plus nivolumab in patients with advanced melanoma who have progressed on anti-PD1 and anti-CTLA-4 drugs or are ineligible for anti-CTLA-4 treatment. "The start of the IGNYTE-3 trial and randomization of the first patient is an important milestone in advance of our planned BLA submission of RP1 in adva
Pre-Biologics License Application (BLA) meeting with the U.S. Food and Drug Administration (FDA) scheduled for September and BLA submission planned for 2H 2024Enrollment of first patient in Phase 3 confirmatory trial of RP1 in advanced melanoma expected in Q3 2024Protocol finalized for registration-directed study of RP2 in uveal melanoma with study initiation activities underway WOBURN, Mass., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ:REPL), a clinical stage biotechnology company pioneering the development of a novel class of oncolytic immunotherapies, today announced financial results for the fiscal first quarter ended June 30, 2024 and provided a business update.
WOBURN, Mass., July 30, 2024 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ:REPL), a clinical stage biotechnology company pioneering the development of a novel class of oncolytic immunotherapies, today announced that members from the Replimune management team will host investor meetings at the following two conferences: BTIG Virtual Biotechnology Conference Dates: August 5-6, 2024 2024 Wedbush PacGrow Healthcare Conference Date: Tuesday, August 13, 2024 About Replimune Replimune Group, Inc., headquartered in Woburn, MA, was founded in 2015 with the mission to transform cancer treatment by pioneering the development of a novel portfolio of oncolytic immunotherapies. Replimune's propri
- Led by a life-sciences focused institutional investor, with participation from Redmile Group, RTW Investments, Boxer Capital and other institutional investors - - Financing follows strong primary analysis data from the RP1 IGNYTE clinical trial in anti-PD1 failed melanoma; BLA filing expected in 2H 2024 - - Proceeds enable full commercial scale up to support a potential launch in 2H 2025 - WOBURN, Mass., June 13, 2024 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ:REPL), a clinical stage biotechnology company pioneering the development of a novel class of oncolytic immunotherapies, today announced that it has entered into a securities purchase agreement for a private investme
WOBURN, Mass., June 07, 2024 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ:REPL), a clinical stage biotechnology company pioneering the development of a novel class of oncolytic immunotherapies, today announced that Sushil Patel, Chief Executive Officer of Replimune, will present at the Goldman Sachs 45th Annual Global Healthcare Conference on Tuesday, June 11, 2024 at 2:00 PM ET. A simultaneous webcast will be available in the Investors section of Replimune's website at www.replimune.com. A replay will be available for 30 days following the conference. About Replimune Replimune Group, Inc., headquartered in Woburn, MA, was founded in 2015 with the mission to transform cancer
Primary endpoint data shows 12-month overall response rate (ORR) of 33.6% Biologics license application (BLA) submission intended for 2H 2024; first patient expected to be enrolled in IGNYTE-3 confirmatory trial in Q3 2024 Company to host conference call and webcast today at 8:00 a.m. ET WOBURN, Mass., June 06, 2024 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ:REPL), a clinical stage biotechnology company pioneering the development of a novel class of oncolytic immunotherapies, today announced the topline results from the primary analysis of the IGNYTE clinical trial of RP1 plus nivolumab in anti-PD1 failed melanoma. The results by independent central review show one-third of pat
Barclays analyst Peter Lawson maintains Replimune Group (NASDAQ:REPL) with a Overweight and raises the price target from $13 to $17.
U.S. stock futures were slightly higher this morning, with the Dow futures gaining around 0.1% on Friday. Shares of Vail Resorts, Inc. (NYSE:MTN) fell sharply in today's pre-market trading after the company reported weaker-than-expected results for its third quarter. The company posted quarterly earnings of $9.54 per share, missing market estimates of $10.03 per share. The company’s sales came in at $1.28 billion versus expectations of $1.30 billion, according to data from Benzinga Pro. Vail Resorts shares declined 6.8% to $180.77 in pre-market trading. Here are some big stocks recording losses in today's pre-market trading session. Biomea Fusion, Inc. (NASDAQ:BMEA) shares tu
HC Wainwright & Co. analyst Robert Burns maintains Replimune Group (NASDAQ:REPL) with a Buy and raises the price target from $12 to $17.
U.S. stocks traded mixed toward the end of trading, with the S&P 500 falling around 0.1% on Thursday. The Dow traded up 0.06% to 38,830.40 while the NASDAQ fell 0.16% to 17,160.31. The S&P 500 also fell, dropping, 0.12% to 5,347.42. . Check This Out: Wall Street’s Most Accurate Analysts Give Their Take On 3 Consumer Stocks Delivering High-Dividend Yields Leading and Lagging SectorsConsumer discretionary shares rose by 0.8% on Thursday. In trading on Thursday, utilities shares fell by 0.8%. Top Headline The J. M. Smucker Company (NYSE:SJM) shares gained around 5% on Thursday after the company posted upbeat quarterly earnings. The company reported a fourth-quarter FY
Shares of G-III Apparel Group, Ltd. (NASDAQ:GIII) fell sharply during Thursday's session after the company reported worse-than-expected quarterly sales results. G-III Apparel Group posted adjusted earnings of 13 cents per share, according to data from Benzinga Pro. The company's quarterly sales came in at $609.747 million, missing market estimates of $616.286 million. G-III Apparel Group shares dipped 13.4% to $27.12 on Thursday. Here are some other stocks moving in today’s mid-day session. Gainers Virax Biolabs Group Limited (NASDAQ:VRAX) shares jumped 139.4% to $2.5390. American Oncology Network, Inc. (NASDAQ:AONC) gained 102% to $4.52. American Oncology Network expanded
Gainers Virax Biolabs Group (NASDAQ:VRAX) shares rose 88.8% to $2.02 during Thursday's regular session. The company's market cap stands at $4.7 million. FibroBiologics (NASDAQ:FBLG) shares rose 45.37% to $9.74. The market value of their outstanding shares is at $318.6 million. Aethlon Medical (NASDAQ:AEMD) stock rose 39.58% to $0.61. The company's market cap stands at $3.1 million. American Oncology Network (NASDAQ:AONC) stock rose 32.96% to $3.0. The market value of their outstanding shares is at $30.6 million. Replimune Group (NASDAQ:REPL) shares rose 29.04% to $7.17. The company's market cap stands at $440.6 million. Co-Diagnostics (NASDAQ:CODX) stock rose 27.18% to $1.31. The marke
U.S. stocks traded mixed midway through trading, with the Dow Jones index gaining around 50 points on Thursday. The Dow traded up 0.14% to 38,860.40 while the NASDAQ fell 0.07% to 17,175.73. The S&P 500 also rose, gaining, 0.01% to 5,354.33. Check This Out: Wall Street’s Most Accurate Analysts Give Their Take On 3 Consumer Stocks Delivering High-Dividend Yields Leading and Lagging SectorsConsumer discretionary shares rose by 0.5% on Thursday. In trading on Thursday, utilities shares fell by 0.5%. Top Headline Lululemon Athletica Inc. (NASDAQ:LULU) reported upbeat financial results for its first quarter and authorized a $1 billion increase in its stock repurchase program on
Thursday, Replimune Group Inc (NASDAQ:REPL) released topline results from the primary analysis of the IGNYTE clinical trial of RP1 plus nivolumab in anti-PD1 failed melanoma. Bristol-Myers Squibb Co’s (NYSE:BMY) Nivolumab, sold under the brand name Opdivo, is an anti-cancer medication used to treat several types of cancer. The results show that one-third of patients receiving RP1 plus nivolumab responded to treatment, improving upon the investigator-assessed data presented at ASCO 2024. All responses lasted longer than 6 months from baseline. “The overall strength of the IGNYTE data and safety profile further highlights the potential of RP1 in a difficult treatment setting with limi
SC 13G/A - Replimune Group, Inc. (0001737953) (Subject)
SC 13G/A - Replimune Group, Inc. (0001737953) (Subject)
SC 13G/A - Replimune Group, Inc. (0001737953) (Subject)
SC 13G/A - Replimune Group, Inc. (0001737953) (Subject)
SC 13G/A - Replimune Group, Inc. (0001737953) (Subject)
SC 13G/A - Replimune Group, Inc. (0001737953) (Subject)
SC 13G/A - Replimune Group, Inc. (0001737953) (Subject)
SC 13G - Replimune Group, Inc. (0001737953) (Subject)
SC 13G/A - Replimune Group, Inc. (0001737953) (Subject)
SC 13G - Replimune Group, Inc. (0001737953) (Subject)
Primary endpoint data shows 12-month overall response rate (ORR) of 33.6% Biologics license application (BLA) submission intended for 2H 2024; first patient expected to be enrolled in IGNYTE-3 confirmatory trial in Q3 2024 Company to host conference call and webcast today at 8:00 a.m. ET WOBURN, Mass., June 06, 2024 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ:REPL), a clinical stage biotechnology company pioneering the development of a novel class of oncolytic immunotherapies, today announced the topline results from the primary analysis of the IGNYTE clinical trial of RP1 plus nivolumab in anti-PD1 failed melanoma. The results by independent central review show one-third of pat
RP1 in combination with cemiplimab demonstrated clinically meaningful improvements in complete response rate and duration of response compared to cemiplimab in the CERPASS clinical trial, but did not meet either of the two primary endpoints Positive data update for full 140 patients in the IGNYTE clinical trial cohort of RP1 in anti-PD1 failed melanoma reinforces durable benefit; biologics license application (BLA) submission planned for 2H 2024 RP1 monotherapy data from ARTACUS clinical trial and new data from first 30 patients with anti-PD1 failed non-melanoma skin cancers in IGNYTE trial adds to growing body of evidence supporting the potential of RP1 in difficult to treat skin cancer s
The Company plans to hold a conference call in early December to provide a comprehensive RP1 skin cancer program update including: Topline data from the CERPASS clinical trial of RP1 combined with Libtayo in cutaneous squamous cell carcinomaAn initial data snapshot for all 140 patients in the IGNYTE clinical trial cohort of RP1 in anti-PD1 failed melanomaInitial data from the IGNYTE cohort of RP1 in anti-PD1 failed non-melanoma skin cancersA recap of interim data from the ARTACUS clinical trial of RP1 monotherapy in solid organ transplant recipients with skin cancer recently presented at SITC 2023 WOBURN, Mass., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ:
8-K - Replimune Group, Inc. (0001737953) (Filer)
EFFECT - Replimune Group, Inc. (0001737953) (Filer)
S-3 - Replimune Group, Inc. (0001737953) (Filer)
10-Q - Replimune Group, Inc. (0001737953) (Filer)
8-K - Replimune Group, Inc. (0001737953) (Filer)
EFFECT - Replimune Group, Inc. (0001737953) (Filer)
ARS - Replimune Group, Inc. (0001737953) (Filer)
DEFA14A - Replimune Group, Inc. (0001737953) (Filer)
DEF 14A - Replimune Group, Inc. (0001737953) (Filer)
8-K - Replimune Group, Inc. (0001737953) (Filer)
4 - Replimune Group, Inc. (0001737953) (Issuer)
3 - Replimune Group, Inc. (0001737953) (Issuer)
4 - Replimune Group, Inc. (0001737953) (Issuer)
4 - Replimune Group, Inc. (0001737953) (Issuer)
4 - Replimune Group, Inc. (0001737953) (Issuer)
4 - Replimune Group, Inc. (0001737953) (Issuer)
4 - Replimune Group, Inc. (0001737953) (Issuer)
4 - Replimune Group, Inc. (0001737953) (Issuer)
4 - Replimune Group, Inc. (0001737953) (Issuer)
4 - Replimune Group, Inc. (0001737953) (Issuer)
ROTH MKM initiated coverage of Replimune with a rating of Buy and set a new price target of $17.00
Piper Sandler resumed coverage of Replimune with a rating of Overweight and set a new price target of $44.00
Piper Sandler initiated coverage of Replimune Group with a rating of Overweight and set a new price target of $52.00
BTIG Research resumed coverage of Replimune with a rating of Buy and set a new price target of $60.00
SVB Leerink reiterated coverage of Replimune Group with a rating of Outperform and set a new price target of $49.00 from $55.00 previously
SVB Leerink reiterated coverage of Replimune Group with a rating of Outperform and set a new price target of $55.00 from $56.00 previously
HC Wainwright resumed coverage of Replimune Group with a rating of Buy and set a new price target of $60.00 from $58.00 previously
SVB Leerink reiterated coverage of Replimune Group with a rating of Outperform and set a new price target of $56.00 from $57.00 previously
Philip Astley-Sparke to transition from current role of CEO to Executive Chairman Planned leadership changes position the Company for commercialization Preparations on track to submit RP1 biologics license application (BLA) in 2H 2024 WOBURN, Mass., March 26, 2024 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ:REPL), a clinical stage biotechnology company pioneering the development of a novel class of oncolytic immunotherapies, today announced changes to its executive leadership team designed to support the Company's preparations for the commercial launch of RP1, pending regulatory submission and approval in anti-PD1 failed melanoma. Sushil Patel, Ph.D., will succeed Philip
The company aims to become a global leader in precision oncology by redefining Synthetic Lethality to treat large, currently unserved patient populationsLead program targets Alternative Lengthening of Telomeres (ALT) through the FANCM protein complexCompany backed by leading venture firms, BioGeneration Ventures (BGV) and ForbionWorld-class leadership team with proven experience as entrepreneurs and deep expertise in drug discovery and precision oncology AMSTERDAM and LONDON, Oct. 17, 2023 (GLOBE NEWSWIRE) -- Tessellate BIO, a preclinical stage biotechnology company with a focus on novel Synthetic Lethality approaches, has today emerged from stealth, with an initial €8m in s
WOBURN, Mass., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ:REPL), a clinical stage biotechnology company pioneering the development of a novel portfolio of oncolytic immunotherapies, today announced the appointment of Emily Hill as Chief Financial Officer. Ms. Hill was most recently CFO of the commercial stage biotech company PTC Therapeutics and has more than 15 years of experience in the biotechnology and life sciences industry having held senior financial management and investor relations roles at several leading public biotechnology and pharmaceutical companies. "Emily brings a wealth of financial planning and strategy experience to Replimune that will be impactfu
Mr. Weinand is the former CEO and Chairman of the Board at Bayer Pharma AG, leading Bayer's fully integrated $20 billion healthcare business Mr. Weinand is a seasoned business leader with over 25 years of experience leading business and strategic operations for companies including Bayer, Pfizer, Bristol Myers Squibb, Sanofi, and Otsuka Coya Therapeutics, Inc. (NASDAQ:COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company developing biologics and cell therapies intended to enhance the function of Regulatory T Cells (Tregs), today announced that it has appointed Mr. Dieter Weinand to its board of directors, effective immediately. Coya will leverage Mr. Weinand's extens
Topline data from the registration-directed CERPASS clinical trial of RP1 combined with Libtayo® (cemiplimab-rwlc) in cutaneous squamous cell carcinoma expected in early Q4 2023 and Biologics License Application submission anticipated in Q1/2 2024 Cost sharing collaboration in cutaneous squamous cell carcinoma in the neoadjuvant setting entered into with Incyte Data snapshot for all 141 patients in the IGNYTE clinical trial cohort of RP1 in anti-PD1 failed melanoma expected Q4 2023 RP2 and RP3 Phase 2 programs; third-line colorectal cancer clinical trial initiated, first- and second-line hepatocellular carcinoma trials expected to initiate this quarter; Phase 1 clinical trial
WOBURN, Mass., June 05, 2023 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ:REPL), a clinical stage biotechnology company pioneering the development of a novel portfolio of tumor-directed oncolytic immunotherapies, today announced the appointment of Veleka R. Peeples-Dyer to the Company's Board of Directors effective June 1, 2023. "We are pleased to welcome Veleka to Replimune's Board of Directors," said Philip Astley-Sparke, Chief Executive Officer of Replimune. "Veleka is a highly accomplished life sciences executive, experienced attorney and compliance professional with over 24 years of her practice dedicated to the life sciences industry assisting with building legal and compliance
NAARDEN, Netherlands and MUNICH, Germany, May 04, 2023 (GLOBE NEWSWIRE) -- Forbion, a leading European life sciences venture capital firm, announces the appointment of Silva Deželan PhD, as Forbion's first Head of Impact & ESG. Silva has over 15 years of experience in ESG integration, sustainability and impact investing, including private equity, most recently as ESG Director at Stafford Capital Partners and before that as Director, Sustainability, Private Equity at Robeco. Silva contributes her knowledge of ESG best-practice to a number of professional organizations, including as vice-chair of Invest Europe's ESG Committee, and as a member of the Responsible Investment Committee of the Du
WOBURN, Mass., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ:REPL), a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic immunotherapies (TDOIs), announced today the appointment of Christopher Sarchi as Replimune's Chief Commercial Officer and the appointment of Sushil Patel, Ph.D., previously Replimune's Chief Commercial Officer, to a newly created position of Chief Strategy Officer, effective immediately. "These leadership appointments provide broad strategic and operational commercial acumen as we ramp up our commercial planning ahead of the potential 2024 commercial launch of RP1," said Philip Astley-Sparke, C
WOBURN, Mass., Dec. 02, 2021 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ:REPL), a biotechnology company developing a range of product candidates derived from its oncolytic immuno-gene therapy platform, today announced the appointment of Christy Oliger to the Company's Board of Directors effective December 1, 2021. "We are delighted to welcome Christy to Replimune's Board of Directors," said Philip Astley-Sparke, Chief Executive Officer of Replimune. "Christy brings nearly 30 years of commercial and business experience in the pharmaceutical and biotechnology industry foremostly in oncology. We look forward to working with Christy and believe her guidance and input will strengthen our
WOBURN, Mass., May 10, 2021 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ:REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic® platform, today announced the strengthening of its executive team with the appointment of Tanya Lewis to a newly created position of Chief Development Operations Officer effective May 10, 2021. Ms. Lewis previously served on Replimune's board of directors and resigned on May 7th in order to join the executive team. Ms. Lewis joins from Karyopharm Therapeutics, a publicly traded biopharmaceutical company, where she served as Executive Vice President, Chief Regulatory Strategy and Strategic Operations Officer and